Esperion announced the expansion of its development portfolio with a new program aimed at treating primary sclerosing cholangitis (PSC), a rare liver disease. The company confirmed the effectiveness ...
RAS is the most mutated oncogene in cancer (about 30% rate), where mutations in KRAS are the most prevalent. The approval of covalent KRAS G12C inhibitors has shown allosteric inhibition of KRAS to be ...
DENVER -- Two drug candidates to expand oral therapy options for psoriasis had similar and consistent performances in separate phase III clinical trials reported here. The allosteric TYK2 inhibitor ...
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results